TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04462731

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-surgical root canal treatment filled with WVT
Description: All eligible teeth were isolated with a rubber dam during root canal treatment. The procedures were performed under a microscope (OPMI Pico; Carl Zeiss, Gottingen, Germany). After access, location of canals, and determination of working length (WL) with Root ZX II apex locator (J Morita, Kyoto, Japan), the canals were instrumented using various .04 taper rotary NiTi instruments to a minimum apical size of 35. 4% Sodium hypochlorite was used as the main irrigant with a 31-gauge needle. 17% EDTA was used as the final irrigant. Passive ultrasonic irrigation with size 20 Acteon tip inserted 2mm short of WL was performed with both 4% sodium hypochlorite and 17% EDTA for 10 seconds in each canal. After final irrigation, the canals were dried with paper points. The master gutta-percha cone fit was verified with periapical radiographs before filling the tooth. WVT was used to fill the tooth when the months were January, March, May, July, September, and November.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical root canal treatment filled with SBT
Description: All eligible teeth were isolated with a rubber dam during root canal treatment. The procedures were performed under a microscope (OPMI Pico; Carl Zeiss, Gottingen, Germany). After access, location of canals, and determination of working length (WL) with Root ZX II apex locator (J Morita, Kyoto, Japan), the canals were instrumented using various .04 taper rotary NiTi instruments to a minimum apical size of 35. 4% Sodium hypochlorite was used as the main irrigant with a 31-gauge needle. 17% EDTA was used as the final irrigant. Passive ultrasonic irrigation with size 20 Acteon tip inserted 2mm short of WL was performed with both 4% sodium hypochlorite and 17% EDTA for 10 seconds in each canal. After final irrigation, the canals were dried with paper points. The master gutta-percha cone fit was verified with periapical radiographs before filling the tooth. SBT was used to fill the tooth when the months were February, April, June, August, October, and December.
Study: NCT03241134

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Dry needling (DN) is a myofascial treatment technique, in which a thin, solid filiform needle is inserted directly into the MTrP. During dry needling, local twitch responses (LTR) can be elicited. These are involuntary contractions of muscle fibers, leading to muscle relaxation, an increase in blood flow,recovery of the muscle metabolism and thus a reduction of pain and stiffness.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham needling
Description: During sham needling, a solid, filiform needle is inserted in the skin surface at the trigger point location, without penetrating the fascia and muscle tissue.
Study: NCT00967473

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACRYSOF® Single-Piece NATURAL Toric IOL Model SN60T9 and Model SN60T8.
Description: ACRYSOF® Single-Piece Toric NATURAL Intraocular Lens (IOL) Model SN60T9 in the first eye and either the ACRYSOF® Single-Piece Toric NATURAL IOL Model SN60T9 or Model SN60T8 in the second eye.
Study: NCT03529552

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anterior Cruciate Ligament Reconstruction
Description: Placement of an SMS bioresorbable interference screw (DEDIENNE Santé)
Study: NCT00303485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D and calcium supplementation
Description: As prescribed
Study: NCT03023124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: Treatment with trabectedin repeated every 21 days for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin
Description: Treatment with Adriamycin at day 1 every 21 days for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Treatment with Dacarbazine at days 1 and 2 every 21 days for 6 cycles
Study: NCT03982069

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FluMist live attenuated influenza vaccine
Description: Participants randomized to this study influenza vaccine arm will receive FluMist live attenuated influenza vaccine at baseline after the baseline blood draw is complete.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Flucelvax inactivated influenza vaccine
Description: Participants randomized to this study influenza vaccine arm will receive Flucelvax cell-culture inactivated influenza vaccine at baseline after the baseline blood draw is complete.
Study: NCT03841305

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver preparation before major hepatectomy
Description: Simultaneous portal and hepatic vein embolization versus Portal vein embolization, also called venous deprivation OR portal vein embolization.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Liver preparation before major hepatectomy
Description: Simultaneous portal and hepatic vein embolization versus Portal vein embolization, also called venous deprivation OR portal vein embolization.
Study: NCT04342026

Intervention type: OTHER
Intervention: Measure of the exposure of parent of male with /without cryptorchidism to endocrine disruptors
Description: Measure of the exposure of parent of patient with/without cryptorchidism to endocrine disruptors (job exposure, during pregnancy)
Study: NCT00303485

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D and calcium supplementation
Description: As prescribed
Study: NCT00303485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibandronate [Bonviva/Boniva]
Description: 150mg po monthly for 6 months
Study: NCT03896945

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-786
Description: oral capsules
Study: NCT01207752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systane Balance
Description: Artificial tear emulsion drop

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optive Lubricant Eye Drops
Description: Artificial tear eye drop
Study: NCT01193114

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ecologically Based Treatment (EBT)
Description: Substance abuse treatment (the Community Reinforcement Approach), case management and housing.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: Treatment/intervention as normally provided by community service agencies that service substance abusing homeless families.
Study: NCT00856726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1-34 parathyroid infusion
Description: 1-34 parathyroid infusion at 0.055 mcg/kg/hr for 6 hours
Study: NCT03594136

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Raumedic Neurovent-P-tel
Description: Insertion of a Neurovent-P-tel in adults to study normal intracranial pressure
Study: NCT02649894

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Approved Uncoated PleurX Indwelling Pleural Catheter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental: Silver Nitrate Coated Indwelling Pleural Catheter (SNCIPC)
Study: NCT03666689

Intervention type: PROCEDURE
Intervention: surgical technique
Description: surgical reconstruction

Intervention type: PROCEDURE
Intervention: surgical technique
Description: surgical reconstruction
Study: NCT00643331

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise performed at gym and at home comprising strength, balance and impact exercise
Study: NCT01813136

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuous pazopanib (Arm A)
Description: Daily oral administration of pazopanib 800mg (28 days cycles) from randomization until progression (according to RECIST 1.1) under treatment, after an initial period of 6 cycles (28 days) of daily administration of pazopanib 800mg from inclusion until randomization
Study: NCT00973323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xarelto (Rivaroxaban, BAY59-7939)
Description: 2.5mg bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xarelto (Rivaroxaban, BAY59-7939)
Description: 5mg bid
Study: NCT01813136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intermittent pazopanib (Arm B)
Description: Temporary discontinuation of pazopanib at randomization, after an initial period of 6 cycles (28 days) of daily administration of pazopanib 800mg from inclusion until randomization. Pazopanib will be reintroduced for 6 cycles of 28 days, with daily administration of pazopanib 800mg, as soon as the patient relapses (progressive disease according to RECIST 1.1). At the end of this additional 6 cycles, study drug will be stopped a second time.~This sequential scheme will be maintained until the patient experiences on-treatment progression
Study: NCT00973323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xarelto (Rivaroxaban, BAY59-7939)
Description: 10mg bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Dose-adjusted warfarin based on target INR values
Study: NCT02843503

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arterialized-venous reference (YSI)
Description: All patients will be fitted with the a CGM system, Dexcom G5 Mobile, patients receive an iv-catheter to sample venous blood. The samples will be arterialized using a heated-hand-box (arterialized-venous reference (YSI). Blood will be drawn for the determination of glucose concentrations using arterialized-venous sampling techniques per YSI.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Venous reference measurement (YSI)
Description: All patients will be fitted with the a CGM system, Dexcom G5 Mobile, patients receive an iv-catheter to sample venous blood. Blood will be drawn for the determination of glucose concentrations using venous sampling techniques measured per YSI.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Capillary reference (SMBG)
Description: All patients will be fitted with the a CGM system, Dexcom G5 Mobile, patients receive vingerstick measurements to sample capillary blood measured per Self Monitoring of Blood Glucose (SMBG) device.
Study: NCT02905669

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoFLIP
Description: Esophago-gastric junction distensibility will be assessed in patients thanks to impedance planimetry using EndoFLIP device
Study: NCT04916912

Intervention type: PROCEDURE
Intervention: coronary artery bypass grafting
Description: Coronary artery bypass surgery is a surgical procedure to restore normal blood flow to an obstructed or stenotic coronary artery.

Intervention type: PROCEDURE
Intervention: coronary artery bypass grafting
Description: Coronary artery bypass surgery is a surgical procedure to restore normal blood flow to an obstructed or stenotic coronary artery.
Study: NCT02812719

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycolic acid peel alone
Description: One of two sides of the face will be randomly treated with glycolic acid peel 35% alone.~This treatment will be administered at visit 1 (but to entire face) and 3 subsequent visits (to one randomly selected side of the face), for a total of 4 treatments at 2 week intervals

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycolic and salicylic acid peel
Description: The other randomly chosen side of the face will be treated with glycolic acid peel 35% followed by salicylic acid peel 20%, as a combination treatment.~This treatment will be administered at visits 2, 3 and 4 (to one randomly selected side of the face), for a total of 3 treatments at 2 week intervals.
Study: NCT01616680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT02431078

Intervention type: PROCEDURE
Intervention: Routine comprehensive treatment
Description: Radical gastrectomy for gastric cancer and postoperative adjuvant chemotherapy

Intervention type: PROCEDURE
Intervention: Routine comprehensive treatment
Description: Radical gastrectomy for gastric cancer and postoperative adjuvant chemotherapy
Study: NCT01963845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03482037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rec 0/0438 1 mg or Rec 0/0438 2 mg
Description: Each vial content will be administered via the catheter used for the self-catheterization

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Each vial content will be administered via the catheter used for the self-catheterization
Study: NCT01357551

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maintenance intervention
Description: Theoretically-informed maintenance intervention that involves in-person group visits that transition to individualized telephone calls, and the frequency of contact gradually decreases over time.
Study: NCT01073384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGX201 (delayed release beclomethasone 17,21-dipropionate)
Description: Delayed release beclomethasone 17,21-dipropionate before the first administration of radiation therapy continuing for 7 days after the end of radiation therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGX201 (delayed release beclomethasone 17,21-dipropionate)
Description: Delayed release beclomethasone 17,21-dipropionate before the first administration of radiation therapy continuing for 7 days after the end of radiation therapy.
Study: NCT01237600

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cultivated limbal transplantation
Description: Cultivated corneal epithelial stem cell transplantation. Autograft, Living related allograft, and Cadaveric allograft
Study: NCT02998658

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vaginal cuff closure using barbed sutures
Description: Vaginal cuff will be closed using a 24-cm × 24-cm 0 polydioxanone double-armed suture on a 26-mm half-circle reverse cutting needle( STRATAFIX™ Spiral PDO Knotless Tissue Control Device, Ethicon Inc , Somerville, NJ, USA )
Study: NCT00615199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: administration via oral route twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: administration via oral route twice daily
Study: NCT00147459

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HBV vaccine booster
Study: NCT03197441

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma
Description: Intraoperative platelet-rich plasma injection during arthroscopic knee surgery
Study: NCT03997630

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow Oxygenation
Description: Interventional group: All patients included in this group will receive a continuous heated and humidified high-flow (30 to 60 l/min) oxygenation with a nasal cannula for 48 hours. Initially, flow rate will be started at 50 l/min with a FiO2 at 50%. According to the protocol, flow rate and FiO2 will be titrated on SpO2 and respiratory tolerance. Weaning and failure of high-flow oxygenation are described in detail in the study protocol.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard oxygen
Description: Control group: All patients included in this group will receive a low flow oxygenation (flow rate \< 15 l/min) with nasal cannula (flow rate ≤ 6 l/min) or non-rebreathing mask (flow rate ≥ 7 l/min).
Study: NCT02735109

Intervention type: OTHER
Group type: OTHER
Intervention: photographies
Description: cells description by taken photographies vith confocal microscope (VivaScope 3000)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: biopsy normal area
Description: biopsy done to compare with abnormal area
Study: NCT01315431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesetaxel plus capecitabine
Description: Study medication, which will include tesetaxel capsules and capecitabine tablets, will be administered orally for two 21-day cycles. In each cycle, tesetaxel will be administered at a dose of 27 mg/m2 on Day 1, and capecitabine will be administered in Cohort 1 at a dose of 2000 mg/m2/day and in Cohort 2 at a dose of 1750 mg/m2/day (in 2 equally divided doses) on Day 1 through Day 14.~At the conclusion of Cycle 2, patients who, in the opinion of the investigator, appear to have benefitted from protocol therapy may receive up to 6 additional cycles under a separate protocol.
Study: NCT02203357

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis B vaccine
Description: Hepatitis B vaccine, 60 μg/1ml recombinant hepatitis B vaccine,20 μg/1ml recombinant hepatitis B vaccine, Shenzhen Kangtai Biological Products Co, LTD.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine
Description: Hepatitis B vaccine, 60 μg/1ml recombinant hepatitis B vaccine,20 μg/1ml recombinant hepatitis B vaccine, Shenzhen Kangtai Biological Products Co, LTD.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine
Description: Hepatitis B vaccine, 60 μg/1ml recombinant hepatitis B vaccine,20 μg/1ml recombinant hepatitis B vaccine, Shenzhen Kangtai Biological Products Co, LTD.
Study: NCT01288963

Intervention type: DRUG
Intervention: IL-2
Description: Observation only
Study: NCT03668678

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iGrow Readers Curriculum
Description: As part of the iGrow Readers curriculum, the primary teacher first reads a book as a group with a specific health behavior theme. Then, children participate in nutrition and physical activities that relate and reinforce the lessons learned in the book. Informational newsletters highlighting healthy behaviors from the stories' themes are provided to parents. All implementation strategies are reinforced by research to promote positive choices in young children's health behaviors through the use of literature and language strategies and modeling of others in the children's microsystems.
Study: NCT00172029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Study: NCT02263963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: In this arm as described above the intervention will be TAP block injection under ultrasound guidance using Exparel.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAP Block
Description: no intervention will be done to this arm.
Study: NCT00648778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loxapine Succinate Capsules 25 mg
Description: 25mg, single dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loxitane® Capsules 25 mg
Description: 25mg, single dose fasting
Study: NCT00344448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raptiva
Description: During the first phase of the study, subjects are randomized in a double blind fashion to receive weekly subcutaneous injections of efalizumab (Raptiva) or placebo (weeks 0-12). The second 12 weeks long phase is open label with all subjects receiving weekly subcutaneous injections of efalizumab.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Raptiva
Description: During the first phase of the study, subjects are randomized in a double blind fashion to receive weekly subcutaneous injections of efalizumab (Raptiva) or placebo (weeks 0-12). The second 12 weeks long phase is open label with all subjects receiving weekly subcutaneous injections of efalizumab.
Study: NCT02827955

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gamma Knife® radiosurgery bilateral
Study: NCT03196063

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Eccentric
Description: Exercises based on eccentric contractions of the quadriceps femoris muscle, using a 15º inclined plane. A serie of 15 repetitions of the squat will be performed, with the frequency of three times a week for eight weeks. The load of the exercises will be increased weekly.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Protocol
Description: Protocol based on the Heavy Slow resistance program, with the addition of an isometric phase at the beginning of the protocol, and with exercises using body weight without the use of mechanotherapy.
Study: NCT01126944

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: heart mate II
Description: left ventricular assist device
Study: NCT04371939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romiplostim
Description: Participants will receive romiplostim at an initial dose of 9 µg/kg subcutaneously per week for at least 1 month depending on their response to study drug.~Patients failing to achieve a complete platelet response cross over to arm II.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Participants will receive eltrombopag at a dose of 2-3mg/kg daily (ages 0 to 5 years) and 75 mg/daily (\>6 years) for at least 1 month depending on their response to study drug.~Patients failing to achieve a complete platelet response switch to arm I.
Study: NCT04003740

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home-based transcranial direct current stimulation
Description: The stimulation protocol will include one daily stimulation during the first 4 weeks, 2 weekly stimulations for the next 4 weeks, and one weekly stimulation over the last 4 weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Home-based transcranial direct current stimulation
Description: The stimulation protocol will include one daily stimulation during the first 4 weeks, 2 weekly stimulations for the next 4 weeks, and one weekly stimulation over the last 4 weeks.
Study: NCT04431492

Intervention type: PROCEDURE
Intervention: CABG
Description: aminoacids and NO levels
Study: NCT02435420

Intervention type: DEVICE
Intervention: EMPERION Modular Primary Stem
Description: Primary total hip arthroplasty using the EMPERION Modular Primary Stem
Study: NCT00099658

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal polysaccharide-protein conjugate vaccine
Description: Injection administered three times before the age of 24 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal polysaccharide-protein conjugate vaccine
Description: Injection administered three times before the age of 24 weeks
Study: NCT02998658

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal cuff closure using conventional sutures
Description: Vaginal cuff will be closed using 1-0 polyglactin 910 suture(VICRYL™.; Ethicon Inc, Sommerville, NJ) .